ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. 

Biotechnology

ALX Oncology

Jaume Pons

Sue Naim

Yeong-Liang Lin

Marija Vrljic

Hadi Falahatpisheh

Sophia Randolph

Peter García

Hank Stern

Susan Vermeir

Chris Byrd

Athanasios Tsiatis

Michael Chang

Jeanne Jew

Clinical Development and Operations

Leadership Team

Regulatory Affairs and Compliance

Teams at ALX Oncology

Clinical Development and Operations

Leadership Team

Regulatory Affairs and Compliance